Diabetic cognitive impairment
Conditions
Interventions
Intervention group:conventional therapy plus retagliptin
Control group:Conventional therapy plus placebo
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 40-75 years, self-reported without significant visual or hearing impairment; 2. Patients diagnosed with T2D-MCI; 3. Stable blood sugar treatment for >=3 months (HbA1c 7.0%-9.0%); 4. Recently treated only with regular insulin and metformin; 5. Clear awareness, communication is unobstructed, voluntarily participating with informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Severe mental illnesses (such as major depression) or neurological diseases (e.g., myelitis, stroke, or brain tumor); 2. Severe cognitive impairments, hearing, and vision impairments that prevent participants from cooperating while completing the scale; 3. History of alcoholism, drug addiction, carbon monoxide poisoning, hypothyroidism, vitamin B12 deficiency, folic acid deficiency, or other serious chronic diseases; 4. Suffering from malignant tumors, hematological, autoimmune, and related diseases; 5. History of serious illnesses, such as diseases of the heart, liver, kidneys, or hematopoietic system; 6. Use of other DPP-4 inhibitors or GLP-1 receptor agonists.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment (MoCA) Score;Brief Mental State Evaluation Scale (MMSE) Score;Neurofilament Light Chain (NfL) ;Glial Fibrillary Acidic Protein (GFAP);Insulin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid;Blood Glucose;ß-amyloid protein 42;Phosphorylated tau protein; | — |
Countries
China
Contacts
Public ContactChangjiang Ying
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed